Inventor
PERUMAL ASHOK
US26 patents
⚠️ This page may combine multiple inventors who share the name “PERUMAL ASHOK”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
TRIS PHARMA INC
15 patentsUS10857143B2Dec 8, 2020
Methylphenidate extended release chewable tablet
TRIS PHARMA INC45 citations98
US10507203B2Dec 17, 2019
Methylphenidate extended release chewable tablet
TRIS PHARMA INC42 citations98
US9844545B2Dec 19, 2017
Methylphenidate extended release chewable tablet
TRIS PHARMA INC43 citations98
US9844544B2Dec 19, 2017
Methylphenidate extended release chewable tablet
TRIS PHARMA INC46 citations98
US9545399B2Jan 17, 2017
Methylphenidate extended release chewable tablet
TRIS PHARMA INC50 citations98
US9295642B2Mar 29, 2016
Methylphenidate extended release chewable tablet
TRIS PHARMA INC61 citations98
US9180100B2Nov 10, 2015
Methylphenidate extended release chewable tablet
TRIS PHARMA INC55 citations98
US9040083B2May 26, 2015
Orally effective methylphenidate extended release powder and aqueous suspension product
TRIS PHARMA INC51 citations98
US8999386B2Apr 7, 2015
Methylphenidate extended release chewable tablet
TRIS PHARMA INC56 citations98
US8956649B2Feb 17, 2015
Orally effective methylphenidate extended release powder and aqueous suspension product
TRIS PHARMA INC51 citations98
US8778390B2Jul 15, 2014
Orally effective methylphenidate extended release powder and aqueous suspension product
TRIS PHARMA INC62 citations98
US8563033B1Oct 22, 2013
Orally effective methylphenidate extended release powder and aqueous suspension product
TRIS PHARMA INC67 citations98
US11103494B2Aug 31, 2021
Methylphenidate extended release chewable tablet
TRIS PHARMA INC5 citations84
US11103495B2Aug 31, 2021
Methylphenidate extended release chewable tablet
TRIS PHARMA INC5 citations84
US11633389B2Apr 25, 2023
Methylphenidate extended release chewable tablet
TRIS PHARMA INC0 citations62
TULEX PHARMACEUTICALS INC
8 patentsUS12343372B2Jul 1, 2025
Desmopressin oral compositions
TULEX PHARMACEUTICALS INC2 citations72
US12214010B2Feb 4, 2025
Desmopressin oral compositions
TULEX PHARMACEUTICALS INC2 citations72
US11911362B2Feb 27, 2024
Compositions and methods for treating epilepsy, seizures and other conditions
TULEX PHARMACEUTICALS INC1 citations72
US11826343B2Nov 28, 2023
Compositions and methods for treating epilepsy, seizures and other conditions
TULEX PHARMACEUTICALS INC1 citations72
US11633374B2Apr 25, 2023
Compositions and methods for treating epilepsy, seizures and other conditions
TULEX PHARMACEUTICALS INC2 citations72
US11433046B2Sep 6, 2022
Compositions and methods for treating epilepsy, seizures and other conditions
TULEX PHARMACEUTICALS INC3 citations72
US12290503B2May 6, 2025
Compositions and methods for treating epilepsy, seizures and other conditions
TULEX PHARMACEUTICALS INC0 citations62
US12576125B2Mar 17, 2026
Desmopressin oral compositions
TULEX PHARMACEUTICALS INC0 citations60
MEHTA KETAN
3 patentsUS8287903B2Oct 16, 2012
Orally effective methylphenidate extended release powder and aqueous suspension product
MEHTA KETAN88 citations99
US8465765B2Jun 18, 2013
Orally effective methylphenidate extended release powder and aqueous suspension product
MEHTA KETAN71 citations98
US8202542B1Jun 19, 2012
Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings
MEHTA KETAN132 citations95